<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39313857</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial.</ArticleTitle><Pagination><StartPage>2402644</StartPage><MedlinePgn>2402644</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2402644</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2402644</ELocationID><Abstract><AbstractText>NCT04993365 (ClinicalTrials.gov).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhuoqun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Development, Sinovac Life Sciences Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhuhang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Development, Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Qun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Statistics Sciences, Beijing KeyTech Statistical Consulting Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lianhao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Development, Sinovac Life Sciences Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hengming</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Development, Sinovac Biotech Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Zhifang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jikai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Products Monitoring and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04993365</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000706269">SARS-CoV-2 inactivated vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722216">sinovac COVID-19 vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Co-administration</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">inactivated EV71 vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>Some of the authors are currently employees by founder (Sinovac), if needed to be declear, ‘Zhuoqun Sun and Lianhao Wang are current employees of Sinovac Life Sciences Co., Ltd. Xing Meng and Hengming Zhang are current employees of Sinovac Biotech Co., Ltd. All the other authors have no conflicts of interest to declare’.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39313857</ArticleId><ArticleId IdType="pmc">PMC11423659</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2402644</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO coronavirus (COVID-19) dashboard. WHO coronavirus (COVID-19) dashboard | WHO coronavirus (COVID-19) dashboard with vaccination data. [accessed 2024 Jun
16]. https://data.who.int/dashboards/covid19/cases?n=o.</Citation></Reference><Reference><Citation>Susskind D, Vines D.. The economics of the COVID-19 pandemic: an assessment. Oxford Rev Econ Policy. 2020;36(Supplement_1):1–8. doi:10.1093/oxrep/graa036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxrep/graa036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199–213. doi:10.1007/s15010-020-01516-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01516-2</ArticleId><ArticleId IdType="pmc">PMC7472674</ArticleId><ArticleId IdType="pubmed">32886331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, Ng LPW, Wong YKE, Pei XM, Li MJW, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877–88. doi:10.1080/14787210.2021.1863146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1863146</ArticleId><ArticleId IdType="pubmed">33306423</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Coronavirus disease (COVID-19). [accessed 2024 Apr
2]. https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-%28covid-19%29.</Citation></Reference><Reference><Citation>Zimmermann P, Pittet LF, Finn A, Pollard AJ, Curtis N. Should children be vaccinated against COVID-19? Arch Dis Child. 2022;107(3):1.4–8. doi:10.1136/archdischild-2021-323040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2021-323040</ArticleId><ArticleId IdType="pubmed">34732388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):276–88. doi:10.1016/s1473-3099(20)30651-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30651-4</ArticleId><ArticleId IdType="pmc">PMC7431129</ArticleId><ArticleId IdType="pubmed">32818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao CM, Orenstein WA, Anderson EJ. The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children. Clin Infect Dis. 2021;72(3):515–8. doi:10.1093/cid/ciaa712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa712</ArticleId><ArticleId IdType="pmc">PMC7314192</ArticleId><ArticleId IdType="pubmed">33527122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MA. Children’s heart and COVID-19: up-to-date evidence in the form of a systematic review. Eur J Pediatr. 2020;179(7):1079–87. doi:10.1007/s00431-020-03699-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03699-0</ArticleId><ArticleId IdType="pmc">PMC7261213</ArticleId><ArticleId IdType="pubmed">32474800</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391–8. doi:10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Orgnization . WHO Expert Committee on Biological Standardization-Annex 3 Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated). WHO Technical Report Series. 2021. May 11;1030:164–223.</Citation></Reference><Reference><Citation>Li XW, Ni X, Qian SY, Wang Q, Jiang RM, Xu WB, Zhang Y-C, Yu G-J, Chen Q, Shang Y-X, et al. Chinese guidelines for the diagnosis and treatment of hand, foot and mouth disease (2018 edition). World J Pediatr. 2018;14(5):437–47. doi:10.1007/s12519-018-0189-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-018-0189-8</ArticleId><ArticleId IdType="pubmed">30280313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Liu F, Qi H, Tu W, Ward MP, Ren M, Zhao Z, Su Q, Huang J, Chen X, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013−2019: a population-based study. The Lancet Reg Health - West Pac. 2022;20:100370. doi:10.1016/j.lanwpc.2021.100370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum Vaccin Immunother. 2018;14(6):1517–23. doi:10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YB, Zeng N, Yuan K, Tian SS, Yang YB, Gao N, Chen X, Zhang A-Y, Kondratiuk AL, Shi P-P, et al. Prevalence and risk factor for long COVID in children and adolescents: a meta-analysis and systematic review. J Infect Public Health. 2023;16(5):660–72. doi:10.1016/j.jiph.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC9990879</ArticleId><ArticleId IdType="pubmed">36931142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, Liang Z-L, Xia J-L, Dai Q-G, Hu Y-L, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol. 2013;20(12):1805–11. doi:10.1128/cvi.00491-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cvi.00491-13</ArticleId><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group a meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis. 2019;220(3):392–9. doi:10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. doi:10.1016/s1473-3099(20)30843-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>